chr10:129467190:> Detail (hg38)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr10:131,265,454-131,569,247 |
| hg38 | chr10:129,467,190-129,770,983 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
[No Data.]
DisGeNET
| Score | Disease name | Description | Source | Pubmed | Links |
|---|---|---|---|---|---|
| 0.023 | squamous cell carcinoma | Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell c... | BeFree,GAD,LHGDN | 25728117 | Detail |
| <0.001 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of cervix | NA | BeFree | Detail | |
| <0.001 | chordoma | NA | BeFree | Detail | |
| <0.001 | colitis | NA | BeFree | Detail | |
| 0.001 | ulcerative colitis | NA | BeFree | Detail | |
| 0.080 | Colonic Neoplasms | NA | BeFree,RGD | Detail | |
| <0.001 | Colonic Polyps | The anti-cancer actions of O6-methylguanine-DNA-methyltransferase in relation to... | BeFree | 25443735 | Detail |
| 0.014 | colorectal carcinoma | Activity of temozolomide in patients with advanced chemorefractory colorectal ca... | BeFree | 24379162 | Detail |
| 0.014 | colorectal carcinoma | The objective of this study was to determine the prognostic value of CD133 and M... | BeFree | 25015560 | Detail |
| 0.014 | colorectal carcinoma | Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and l... | BeFree | 25596081 | Detail |
| 0.014 | colorectal carcinoma | Clinicopathological significance and potential drug target of O6-methylguanine-D... | BeFree | 25716203 | Detail |
| 0.014 | colorectal carcinoma | MGMT promoter methylation status in brain metastases from colorectal cancer and ... | BeFree | 25832877 | Detail |
| 0.014 | colorectal carcinoma | We applied artificial neural networks (ANNs) to understand the connections among... | BeFree | 25942531 | Detail |
| 0.029 | Colorectal Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | common variable immunodeficiency | NA | BeFree | Detail | |
| <0.001 | Crohn Disease | NA | BeFree | Detail | |
| 0.002 | Diabetes Mellitus, Non-Insulin-Dependent | NA | GAD | Detail | |
| 0.005 | Endometrial Neoplasms | NA | LHGDN | Detail | |
| 0.004 | Ependymoma | NA | BeFree,LHGDN | Detail | |
| 0.012 | Esophageal Neoplasms | Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in h... | BeFree,GAD | 25520135 | Detail |
| <0.001 | Fanconi anemia | NA | BeFree | Detail | |
| 0.003 | gallbladder neoplasm | NA | LHGDN | Detail | |
| <0.001 | gastroesophageal reflux disease | NA | BeFree | Detail | |
| 0.202 | glioblastoma | Moreover, TRIM24 regulates the expression of DNA repair enzyme O(6)-methylguanin... | BeFree,CTD_human,GAD,LHGDN | 24469053 | Detail |
| 0.202 | glioblastoma | O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation has proven... | BeFree,CTD_human,GAD,LHGDN | 24521400 | Detail |
| 0.202 | glioblastoma | Justifications for withholding alkylating agent chemotherapy in patients with MG... | BeFree,CTD_human,GAD,LHGDN | 24912512 | Detail |
| 0.202 | glioblastoma | A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in gliobl... | BeFree,CTD_human,GAD,LHGDN | 24994119 | Detail |
| 0.202 | glioblastoma | Methylated O6-methylguanin-DNA-methytransferase (MGMT) promoter methylation is a... | BeFree,CTD_human,GAD,LHGDN | 24995467 | Detail |
| 0.202 | glioblastoma | Subtype specific drugs not only showed significant inhibition effects on the in ... | BeFree,CTD_human,GAD,LHGDN | 25084005 | Detail |
| 0.202 | glioblastoma | The most emblematic biomarker in glioblastoma is O6-methylguanine DNA-methyltran... | BeFree,CTD_human,GAD,LHGDN | 25096963 | Detail |
| 0.202 | glioblastoma | O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is reported t... | BeFree,CTD_human,GAD,LHGDN | 25175833 | Detail |
| 0.202 | glioblastoma | These data indicated that MGMT methylation has prognostic significance in patien... | BeFree,CTD_human,GAD,LHGDN | 25211033 | Detail |
| 0.202 | glioblastoma | The prognosis of MGMT promoter methylation in glioblastoma patients of different... | BeFree,CTD_human,GAD,LHGDN | 25230908 | Detail |
| 0.202 | glioblastoma | DGKI methylation status modulates the prognostic value of MGMT in glioblastoma p... | BeFree,CTD_human,GAD,LHGDN | 25233099 | Detail |
| 0.202 | glioblastoma | Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human gliobl... | BeFree,CTD_human,GAD,LHGDN | 25293350 | Detail |
| 0.202 | glioblastoma | Treatment considerations for MGMT-unmethylated glioblastoma. | BeFree,CTD_human,GAD,LHGDN | 25394859 | Detail |
| 0.202 | glioblastoma | MGMT promoter methylation and IDH1/2 mutation status in GBM were also evaluated. | BeFree,CTD_human,GAD,LHGDN | 25429835 | Detail |
| 0.202 | glioblastoma | By univariate and multivariate Cox proportional hazard regression analysis, MGMT... | BeFree,CTD_human,GAD,LHGDN | 25434389 | Detail |
| 0.202 | glioblastoma | The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIM... | BeFree,CTD_human,GAD,LHGDN | 25467143 | Detail |
| 0.202 | glioblastoma | One Gb subtype presented with low expression of the four genes mentioned, and of... | BeFree,CTD_human,GAD,LHGDN | 25562199 | Detail |
| 0.202 | glioblastoma | Assessing MGMT methylation status and its current impact on treatment in gliobla... | BeFree,CTD_human,GAD,LHGDN | 25586425 | Detail |
| 0.202 | glioblastoma | Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas... | BeFree,CTD_human,GAD,LHGDN | 25605197 | Detail |
| 0.202 | glioblastoma | Among these markers, a predictive value was reported in glioblastomas (GBM) for ... | BeFree,CTD_human,GAD,LHGDN | 25682093 | Detail |
| 0.202 | glioblastoma | Prognostic value of MGMT promoter status in non-resectable glioblastoma after ad... | BeFree,CTD_human,GAD,LHGDN | 25723791 | Detail |
| 0.202 | glioblastoma | Long-term survival following metronomic temozolomide was independent from MGMT a... | BeFree,CTD_human,GAD,LHGDN | 25739547 | Detail |
| 0.202 | glioblastoma | Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. | BeFree,CTD_human,GAD,LHGDN | 25755756 | Detail |
| 0.202 | glioblastoma | Two cilengitide regimens in combination with standard treatment for patients wit... | BeFree,CTD_human,GAD,LHGDN | 25762461 | Detail |
| 0.202 | glioblastoma | Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. | BeFree,CTD_human,GAD,LHGDN | 25973069 | Detail |
| 0.176 | Glioma | MGMT (O(6)-methylguanine-DNA methyltransferase) controls DNA repair pathways, an... | BeFree,CTD_human,GAD,LHGDN | 24709436 | Detail |
| 0.176 | Glioma | Using the World Health Organization grade, histological subtype, and molecular v... | BeFree,CTD_human,GAD,LHGDN | 24874469 | Detail |
| 0.176 | Glioma | MGMT testing--the challenges for biomarker-based glioma treatment. | BeFree,CTD_human,GAD,LHGDN | 24912512 | Detail |
| 0.176 | Glioma | Algorithms have been developed to detect the glioma CpG island methylator phenot... | BeFree,CTD_human,GAD,LHGDN | 25028501 | Detail |
| 0.176 | Glioma | (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing... | BeFree,CTD_human,GAD,LHGDN | 25178915 | Detail |
| 0.176 | Glioma | Methylation status of the methyl-guanine methyltransferase (MGMT) promoter is as... | BeFree,CTD_human,GAD,LHGDN | 25340951 | Detail |
| 0.176 | Glioma | Impact on prognosis of the regional distribution of MGMT methylation with respec... | BeFree,CTD_human,GAD,LHGDN | 25682093 | Detail |
| 0.176 | Glioma | IMP3 expression was significantly associated with the absence of mutations of ID... | BeFree,CTD_human,GAD,LHGDN | 25695077 | Detail |
| 0.176 | Glioma | The O6-methylguanine-DNAmethyltransferase (MGMT) promoter methylation and 1p19q ... | BeFree,CTD_human,GAD,LHGDN | 25727224 | Detail |
| <0.001 | Graft-vs-Host Disease | NA | BeFree | Detail | |
| 0.005 | Head and Neck Neoplasms | NA | GAD | Detail | |
| 0.002 | Heartburn | NA | GAD | Detail | |
| 0.003 | hepatitis | NA | LHGDN | Detail | |
| <0.001 | hepatitis A | NA | BeFree | Detail | |
| <0.001 | hepatitis B | NA | BeFree | Detail | |
| <0.001 | Hepatitis, Chronic | NA | BeFree | Detail | |
| <0.001 | Inflammatory Bowel Diseases | MGMT-B gene promoter hypermethylation in patients with inflammatory bowel diseas... | BeFree | 25773792 | Detail |
| 0.009 | Malignant neoplasm of esophagus | Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on e... | BeFree | 22994708 | Detail |
| <0.001 | Malignant tumor of colon | We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar... | BeFree | 18006925 | Detail |
| 0.002 | esophageal carcinoma | Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on e... | BeFree | 22994708 | Detail |
| 0.014 | colorectal carcinoma | O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and ... | BeFree | 16633920 | Detail |
| 0.028 | Malignant neoplasm of lung | MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis. | BeFree | 24390665 | Detail |
| 0.033 | colorectal cancer | We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar... | BeFree | 18006925 | Detail |
| <0.001 | colon carcinoma | We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar... | BeFree | 18006925 | Detail |
| <0.001 | Rectal Carcinoma | We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar... | BeFree | 18006925 | Detail |
| 0.033 | colorectal cancer | O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and ... | BeFree | 16633920 | Detail |
| 0.009 | Malignant neoplasm of prostate | We found that the XRCC1-Arg399Gln AA and the MGMT-Leu84Phe CT+TT genotypes were ... | BeFree | 16030105 | Detail |
| 0.012 | Esophageal Neoplasms | Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on e... | BeFree | 22994708 | Detail |
| 0.001 | prostate carcinoma | We found that the XRCC1-Arg399Gln AA and the MGMT-Leu84Phe CT+TT genotypes were ... | BeFree | 16030105 | Detail |
| 0.014 | colorectal carcinoma | We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Ar... | BeFree | 18006925 | Detail |
| 0.006 | Carcinoma of lung | MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis. | BeFree | 24390665 | Detail |
| 0.002 | Laryngeal neoplasm | NA | GAD | Detail | |
| 0.128 | leukemia | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
| <0.001 | Leukemia, Lymphocytic, Acute, L1 | NA | BeFree | Detail | |
| 0.004 | Leukemia, Myelocytic, Acute | NA | BeFree,LHGDN | Detail | |
| 0.002 | myeloid leukemia | NA | GAD | Detail | |
| <0.001 | Leukemia, Plasma Cell | NA | BeFree | Detail | |
| <0.001 | acute promyelocytic leukemia | NA | BeFree | Detail | |
| <0.001 | Leukoplakia, Oral | NA | BeFree | Detail | |
| <0.001 | Lichen Sclerosus et Atrophicus | NA | BeFree | Detail | |
| <0.001 | liver cirrhosis | NA | BeFree | Detail | |
| <0.001 | Liver diseases | NA | BeFree | Detail | |
| 0.002 | Chronic Obstructive Airway Disease | NA | GAD | Detail | |
| 0.023 | Lung Neoplasms | NA | BeFree,LHGDN | Detail | |
| 0.006 | lymphoma | NA | BeFree,GAD | Detail | |
| 0.005 | Lymphoma, Non-Hodgkin | NA | GAD,LHGDN | Detail | |
| 0.007 | Malignant neoplasm of stomach | The present results indicated that the methylation of p16, CDH1, MGMT, and hMLH1... | BeFree,GAD | 24816738 | Detail |
| 0.007 | Malignant neoplasm of stomach | MGMT gene silencing by promoter hypermethylation in gastric cancer in a high inc... | BeFree,GAD | 25008999 | Detail |
| 0.001 | medulloblastoma | NA | BeFree | Detail | |
| 0.094 | melanoma | MGMT promoter methylation is associated with temozolomide response and prolonged... | BeFree,GAD,LHGDN,RGD | 25400033 | Detail |
| 0.002 | Meningeal Neoplasms | NA | GAD | Detail | |
| 0.006 | meningioma | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Mixed Salivary Gland Tumor | NA | BeFree | Detail | |
| <0.001 | Monoclonal Gammopathy of Undetermined Significance | NA | BeFree | Detail | |
| 0.008 | Mouth Neoplasms | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | multiple myeloma | NA | BeFree | Detail | |
| 0.120 | Necrosis | NA | CTD_human | Detail | |
| 0.010 | Neoplasm Metastasis | NA | BeFree,GAD,LHGDN | Detail | |
| <0.001 | Nervous System Neoplasms | NA | BeFree | Detail | |
| <0.001 | neurofibromatosis 1 | NA | BeFree | Detail | |
| 0.002 | acoustic neuroma | NA | GAD | Detail | |
| 0.003 | oligodendroglioma | NA | BeFree | Detail | |
| <0.001 | osteosarcoma | NA | BeFree | Detail | |
| 0.001 | ovarian carcinoma | Relationship between promoter methylation & tissue expression of MGMT gene in ov... | BeFree | 25579142 | Detail |
| <0.001 | Pancreatic Neoplasm | NA | BeFree | Detail | |
| <0.001 | pancytopenia | NA | BeFree | Detail | |
| <0.001 | papilloma | NA | BeFree | Detail | |
| 0.120 | Peripheral neuropathy | NA | CTD_human | Detail | |
| 0.002 | Pharyngeal Neoplasms | NA | GAD | Detail | |
| 0.001 | pituitary adenoma | PRL-and GH-secreting PAs exist high expression of D2R, responding to dopamine ag... | BeFree | 25027022 | Detail |
| <0.001 | Pituitary Neoplasms | NA | BeFree | Detail | |
| 0.005 | Adenomatous Polyposis Coli | NA | BeFree,LHGDN | Detail | |
| 0.002 | polyps | NA | BeFree | Detail | |
| 0.003 | Precancerous Conditions | NA | BeFree,GAD | Detail | |
| <0.001 | prolactinoma | NA | BeFree | Detail | |
| <0.001 | Prostatic Neoplasms | NA | BeFree | Detail | |
| 0.004 | retinoblastoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | Seizures | NA | BeFree | Detail | |
| <0.001 | silicosis | NA | BeFree | Detail | |
| <0.001 | Skin Neoplasms | NA | BeFree | Detail | |
| 0.003 | Stomach Neoplasms | NA | BeFree,GAD | Detail | |
| 0.003 | Testicular Neoplasms | NA | BeFree,LHGDN | Detail | |
| <0.001 | thymoma | NA | BeFree | Detail | |
| <0.001 | Thyroid Neoplasm | NA | BeFree | Detail | |
| 0.002 | Tobacco use disorder | NA | GAD | Detail | |
| <0.001 | viral hepatitis | NA | BeFree | Detail | |
| 0.004 | B-Cell Lymphomas | NA | BeFree,LHGDN | Detail | |
| 0.005 | diffuse large B-cell lymphoma | NA | BeFree,GAD | Detail | |
| <0.001 | Lymphoma, T-Cell, Cutaneous | NA | BeFree | Detail | |
| <0.001 | Pleural Effusion, Malignant | NA | BeFree | Detail | |
| 0.002 | spina bifida | NA | GAD | Detail | |
| <0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
| <0.001 | Choroid Plexus Neoplasms | NA | BeFree | Detail | |
| <0.001 | acute leukemia | NA | BeFree | Detail | |
| <0.001 | benign neoplasm | NA | BeFree | Detail | |
| <0.001 | Small cell carcinoma of lung | NA | BeFree | Detail | |
| <0.001 | Cutaneous Melanoma | MGMT promoter methylation is associated with temozolomide response and prolonged... | BeFree | 25400033 | Detail |
| 0.002 | esophageal carcinoma | Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in h... | BeFree | 25520135 | Detail |
| 0.006 | Malignant neoplasm of mouth | NA | BeFree,GAD | Detail | |
| <0.001 | Malignant neoplasm of oropharynx | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of pharynx | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of gallbladder | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of testis | NA | BeFree | Detail | |
| 0.002 | Malignant neoplasm of brain | NA | GAD | Detail | |
| <0.001 | Agenesis of corpus callosum | NA | BeFree | Detail | |
| 0.003 | Tumor Progression | O6-methylguanine DNA methyltransferase (MGMT) methylation and protein expression... | BeFree | 25015560 | Detail |
| <0.001 | thymic carcinoma | NA | BeFree | Detail | |
| <0.001 | Neuroectodermal Tumor, Primitive | NA | BeFree | Detail | |
| <0.001 | Adenoma, Villous | NA | BeFree | Detail | |
| <0.001 | Adenomatous Polyps | NA | BeFree | Detail | |
| <0.001 | verrucous carcinoma | NA | BeFree | Detail | |
| <0.001 | Neoplasms, Neuroepithelial | NA | BeFree | Detail | |
| 0.121 | gliosarcoma | NA | BeFree,ORPHANET | Detail | |
| <0.001 | Neuroendocrine Tumors | O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognos... | BeFree | 25584486 | Detail |
| <0.001 | childhood rhabdomyosarcoma | NA | BeFree | Detail | |
| <0.001 | uveal melanoma | NA | BeFree | Detail | |
| 0.001 | Lip and oral cavity carcinoma | NA | BeFree | Detail | |
| 0.002 | Metastatic malignant neoplasm to brain | MGMT promoter methylation status in brain metastases from colorectal cancer and ... | BeFree | 25832877 | Detail |
| <0.001 | gallbladder carcinoma | NA | BeFree | Detail | |
| <0.001 | pancreatic carcinoma | NA | BeFree | Detail | |
| <0.001 | Carcinoma of extrahepatic bile duct | NA | BeFree | Detail | |
| <0.001 | Gastrointestinal Stromal Tumors | NA | BeFree | Detail | |
| <0.001 | Hereditary pancreatitis | Epigenetic inactivation of MGMT in HPCs necessitates the assessment of prognosti... | BeFree | 24521400 | Detail |
| <0.001 | islet cell tumor | Prognostic and predictive roles of MGMT protein expression and promoter methylat... | BeFree | 25012122 | Detail |
| 0.028 | Malignant neoplasm of lung | A single-nucleotide polymorphism (SNP) in an enhancer in the MGMT promoter was p... | BeFree,GAD | 26183928 | Detail |
| <0.001 | Mucosa-Associated Lymphoid Tissue Lymphoma | NA | BeFree | Detail | |
| <0.001 | Turcot syndrome (disorder) | These results suggest that tumor cells with methylated MGMT may undergo positive... | BeFree | 25724300 | Detail |
| <0.001 | Medulloblastoma, Childhood | NA | BeFree | Detail | |
| 0.001 | Metastatic melanoma | NA | BeFree | Detail | |
| 0.003 | Cancer of Head and Neck | NA | BeFree,GAD | Detail | |
| <0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | Notably, we hypothesized that the inhibition of MGMT, a DNA damage response enzy... | BeFree | 25690898 | Detail |
| <0.001 | Lobular carcinoma in situ of breast | NA | BeFree | Detail | |
| 0.123 | Squamous cell carcinoma of esophagus | Promoter methylation of MGMT gene in serum of patients with esophageal squamous ... | BeFree,CTD_human | 25520135 | Detail |
| <0.001 | Adenocarcinoma Of Esophagus | NA | BeFree | Detail | |
| <0.001 | Transitional cell carcinoma of bladder | NA | BeFree | Detail | |
| <0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistan... | BeFree | 26185135 | Detail |
| <0.001 | Solid tumour | NA | BeFree | Detail | |
| <0.001 | diffuse astrocytoma | NA | BeFree | Detail | |
| <0.001 | anaplastic ependymoma | NA | BeFree | Detail | |
| <0.001 | mixed oligodendroglioma-astrocytoma | NA | BeFree | Detail | |
| 0.001 | Primary central nervous system lymphoma | NA | BeFree | Detail | |
| 0.003 | cervix carcinoma | NA | BeFree,GAD | Detail | |
| 0.001 | Tumor necrosis | NA | BeFree | Detail | |
| <0.001 | High-Grade Squamous Intraepithelial Lesions | NA | BeFree | Detail | |
| <0.001 | Hyperplastic Polyp | NA | BeFree | Detail | |
| <0.001 | Tubular adenoma | NA | BeFree | Detail | |
| <0.001 | Tubulovillous adenoma | NA | BeFree | Detail | |
| <0.001 | Non-infiltrating lobular carcinoma | NA | BeFree | Detail | |
| 0.002 | anaplastic astrocytoma | NA | BeFree | Detail | |
| <0.001 | pleomorphic xanthoastrocytoma | NA | BeFree | Detail | |
| 0.120 | giant cell glioblastoma | NA | ORPHANET | Detail | |
| 0.002 | anaplastic oligodendroglioma | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendrog... | BeFree | 25078279 | Detail |
| <0.001 | Malignant neoplasm of liver | Notably, we hypothesized that the inhibition of MGMT, a DNA damage response enzy... | BeFree | 25690898 | Detail |
| <0.001 | Adenoma of lung | NA | BeFree | Detail | |
| <0.001 | Breast Cancer, Familial | NA | BeFree | Detail | |
| <0.001 | pituitary carcinoma | NA | BeFree | Detail | |
| 0.003 | Malignant neoplasm of pancreas | NA | BeFree,GAD | Detail | |
| <0.001 | Cervical intraepithelial neoplasia grade 1 | NA | BeFree | Detail | |
| <0.001 | Cervical intraepithelial neoplasia grade 2 | NA | BeFree | Detail | |
| <0.001 | Hemangiopericytoma of meninges | Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT... | BeFree | 24521400 | Detail |
| 0.009 | Malignant neoplasm of prostate | NA | BeFree,GAD | Detail | |
| 0.003 | endometrial carcinoma | NA | BeFree,GAD | Detail | |
| <0.001 | Secondary malignant neoplasm of liver | NA | BeFree | Detail | |
| 0.002 | body mass | NA | GAD | Detail | |
| <0.001 | Recurrent tumor | NA | BeFree | Detail | |
| 0.009 | Malignant neoplasm of esophagus | Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in h... | BeFree,GAD | 25520135 | Detail |
| <0.001 | Thyroid carcinoma | NA | BeFree | Detail | |
| 0.007 | Malignant glioma | Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against... | BeFree | 25111384 | Detail |
| <0.001 | Osteosarcoma of bone | NA | BeFree | Detail | |
| 0.015 | Carcinogenesis | This study evaluates MGMT promoter methylation in meningeal HPCs to determine it... | BeFree | 24521400 | Detail |
| 0.015 | Carcinogenesis | In conclusion, MGMT methylation is central to the development of cancer that inv... | BeFree | 25596081 | Detail |
| 0.015 | Carcinogenesis | Our data suggests that MGMT promoter hypermethylation could have a potential fun... | BeFree | 25820821 | Detail |
| 0.015 | Carcinogenesis | O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that prot... | BeFree | 26183928 | Detail |
| <0.001 | Chemical Carcinogenesis | NA | BeFree | Detail | |
| <0.001 | Leukemogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Initiation | NA | BeFree | Detail | |
| 0.001 | prostate carcinoma | NA | BeFree | Detail | |
| <0.001 | Epithelial ovarian cancer | The methylation frequencies of the MGMT gene promoter were found to be 29.5, 28.... | BeFree | 25579142 | Detail |
| 0.003 | breast carcinoma | Also, based on their predictive value of response to therapy, the immunohistoche... | BeFree | 25820821 | Detail |
| 0.006 | Carcinoma of lung | A single-nucleotide polymorphism (SNP) in an enhancer in the MGMT promoter was p... | BeFree | 26183928 | Detail |
| <0.001 | Secondary malignant neoplasm of lymph node | NA | BeFree | Detail | |
| <0.001 | colon carcinoma | NA | BeFree | Detail | |
| 0.005 | stomach carcinoma | The present results indicated that the methylation of p16, CDH1, MGMT, and hMLH1... | BeFree | 24816738 | Detail |
| 0.005 | stomach carcinoma | MGMT gene silencing by promoter hypermethylation in gastric cancer in a high inc... | BeFree | 25008999 | Detail |
| <0.001 | Carcinoma of bladder | NA | BeFree | Detail | |
| <0.001 | gastritis h pylori | NA | BeFree | Detail | |
| <0.001 | Pharyngeal Carcinoma | NA | BeFree | Detail | |
| <0.001 | biliary tract cancer | NA | BeFree | Detail | |
| <0.001 | Brain Tumor, Primary | NA | BeFree | Detail | |
| 0.003 | Well Differentiated Oligodendroglioma | NA | BeFree | Detail | |
| <0.001 | Genitourinary Cancer | NA | BeFree | Detail | |
| <0.001 | malignant peripheral nerve sheath tumor | NA | BeFree | Detail | |
| <0.001 | malignant pleural mesothelioma | NA | BeFree | Detail | |
| <0.001 | Helicobacter pylori infection | NA | BeFree | Detail | |
| <0.001 | Myelosuppression | NA | BeFree | Detail | |
| <0.001 | Testicular malignant germ cell tumor | NA | BeFree | Detail | |
| <0.001 | Intraepithelial Neoplasia | NA | BeFree | Detail | |
| <0.001 | ovarian neoplasm | NA | BeFree | Detail | |
| <0.001 | Colorectal cancer metastatic | NA | BeFree | Detail | |
| 0.002 | Polyp of large intestine | NA | GAD | Detail | |
| <0.001 | Papillomavirus Infections | NA | BeFree | Detail | |
| <0.001 | Invasive Ductal Breast Carcinoma | Protein expression and methylation of MGMT, a DNA repair gene and their correlat... | BeFree | 25820821 | Detail |
| <0.001 | Malignant neoplasm of ovary | Relationship between promoter methylation & tissue expression of MGMT gene in ov... | BeFree | 25579142 | Detail |
| 0.002 | Squamous cell carcinoma of the head and neck | NA | BeFree | Detail | |
| <0.001 | sarcoma | NA | BeFree | Detail | |
| <0.001 | Adenoma of large intestine | MGMT hypermethylation is also significantly higher in colorectal adenoma than in... | BeFree | 25716203 | Detail |
| <0.001 | Astrocytoma, low grade | NA | BeFree | Detail | |
| <0.001 | Adenocarcinoma of large intestine | Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in ... | BeFree | 25015560 | Detail |
| <0.001 | Thymoma, type C | NA | BeFree | Detail | |
| <0.001 | Chordoma of clivus | NA | BeFree | Detail | |
| <0.001 | Hereditary Nonpolyposis Colorectal Cancer | NA | BeFree | Detail | |
| <0.001 | Oligodendroglial Neoplasm | NA | BeFree | Detail | |
| <0.001 | Testicular Germ Cell Tumor | NA | BeFree | Detail | |
| <0.001 | Thymic Lymphoma | NA | BeFree | Detail | |
| <0.001 | Epithelioma | NA | BeFree | Detail | |
| <0.001 | Primary Lesion | NA | BeFree | Detail | |
| 0.120 | Micronuclei, Chromosome-Defective | NA | CTD_human | Detail | |
| 0.003 | Mammary Neoplasms | Methylation-specific PCR was carried out to investigate the promoter methylation... | BeFree,LHGDN | 25820821 | Detail |
| <0.001 | Hepatocarcinogenesis | NA | BeFree | Detail | |
| <0.001 | Hereditary Melanoma | NA | BeFree | Detail | |
| 0.002 | Primary Glioblastoma | NA | BeFree | Detail | |
| <0.001 | Low Grade Cervical Squamous Intraepithelial Neoplasia | NA | BeFree | Detail | |
| <0.001 | Malignant Conversion | NA | BeFree | Detail | |
| <0.001 | Secondary Glioblastoma | NA | BeFree | Detail | |
| <0.001 | Skin Carcinogenesis | NA | BeFree | Detail | |
| <0.001 | Tumor Promotion | NA | BeFree | Detail | |
| <0.001 | Xenograft Model | NA | BeFree | Detail | |
| 0.033 | colorectal cancer | Activity of temozolomide in patients with advanced chemorefractory colorectal ca... | BeFree,GAD | 24379162 | Detail |
| 0.033 | colorectal cancer | The objective of this study was to determine the prognostic value of CD133 and M... | BeFree,GAD | 25015560 | Detail |
| 0.033 | colorectal cancer | Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and l... | BeFree,GAD | 25596081 | Detail |
| 0.033 | colorectal cancer | Clinicopathological significance and potential drug target of O6-methylguanine-D... | BeFree,GAD | 25716203 | Detail |
| 0.033 | colorectal cancer | MGMT promoter methylation status in brain metastases from colorectal cancer and ... | BeFree,GAD | 25832877 | Detail |
| 0.033 | colorectal cancer | We applied artificial neural networks (ANNs) to understand the connections among... | BeFree,GAD | 25942531 | Detail |
| <0.001 | smoldering myeloma | NA | BeFree | Detail | |
| 0.001 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
| 0.011 | Glioblastoma multiforme | Moreover, systemic delivery of scL-p53 down-modulates MGMT and induces apoptosis... | BeFree | 24811110 | Detail |
| 0.011 | Glioblastoma multiforme | The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIM... | BeFree | 25467143 | Detail |
| 0.011 | Glioblastoma multiforme | We performed a systematic review to identify articles from the temozolomide era ... | BeFree | 25822375 | Detail |
| 0.011 | Glioblastoma multiforme | Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is ... | BeFree | 25890369 | Detail |
| <0.001 | Cirrhosis | NA | BeFree | Detail | |
| 0.002 | Non-Neoplastic Disorder | Using a 10% cutoff, MGMT methylation was identified in 37% cases of glioblastoma... | BeFree | 25755756 | Detail |
| 0.002 | Non-Neoplastic Disorder | Using a 10% cutoff, MGMT methylation was identified in 37% cases of glioblastoma... | BeFree | 25973069 | Detail |
| <0.001 | Fast acetylator due to N-acetyltransferase enzyme variant | NA | BeFree | Detail | |
| 0.007 | Malignant neoplasm of stomach | Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R39... | BeFree | 20817763 | Detail |
| <0.001 | uterine corpus cancer | NA | BeFree | Detail | |
| <0.001 | low grade glioma | NA | BeFree | Detail | |
| 0.008 | liver carcinoma | Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analy... | BeFree,LHGDN | 25169493 | Detail |
| 0.005 | stomach carcinoma | Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R39... | BeFree | 20817763 | Detail |
| <0.001 | Oropharyngeal Carcinoma | NA | BeFree | Detail | |
| <0.001 | Treatment related leukaemia | NA | BeFree | Detail | |
| <0.001 | Nasopharyngeal carcinoma | O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following... | BeFree | 25693518 | Detail |
| <0.001 | Intramucosal Adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | Colorectal Serrated Adenocarcinoma | NA | BeFree | Detail | |
| <0.001 | FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder) | NA | BeFree | Detail | |
| <0.001 | Triple Negative Breast Neoplasms | Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransf... | BeFree | 24709436 | Detail |
| 0.003 | Infection | NA | LHGDN | Detail | |
| 0.120 | Inflammatory dermatosis | NA | GWASCAT | Detail | |
| 0.015 | adenocarcinoma | NA | BeFree,GAD,LHGDN | Detail | |
| 0.006 | adenoma | In conclusion, MGMT methylation is central to the development of cancer that inv... | BeFree | 25596081 | Detail |
| <0.001 | AIDS related complex | DNA methylation of MGMT may regulate the expression of the gene and be involved ... | BeFree | 25847269 | Detail |
| 0.010 | Astrocytoma | NA | BeFree,LHGDN | Detail | |
| <0.001 | ataxia telangiectasia | Using western blotting it was shown that GA inhibited the protein expressions of... | BeFree | 25862863 | Detail |
| 0.003 | Barrett esophagus | NA | LHGDN | Detail | |
| 0.008 | Biliary Tract Neoplasm | NA | GAD,LHGDN | Detail | |
| 0.010 | Malignant neoplasm of urinary bladder | NA | BeFree,GAD | Detail | |
| 0.143 | Brain Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
| 0.012 | Malignant neoplasm of breast | Also, based on their predictive value of response to therapy, the immunohistoche... | BeFree,GAD | 25820821 | Detail |
| <0.001 | Carcinoid Tumor | NA | BeFree | Detail | |
| <0.001 | Malignant tumor of colon | NA | BeFree | Detail | |
| <0.001 | Malignant neoplasm of endometrium | NA | BeFree | Detail | |
| <0.001 | Rectal Carcinoma | NA | BeFree | Detail | |
| 0.004 | Non-small cell lung carcinoma | NA | BeFree | Detail | |
| 0.176 | Glioma | Interestingly, the risk for glioma was dramatically increased in ionizing radiat... | BeFree | 19124499 | Detail |
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: a systemat... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The anti-cancer actions of O6-methylguanine-DNA-methyltransferase in relation to colon polyps. | DisGeNET | Detail |
| Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promot... | DisGeNET | Detail |
| The objective of this study was to determine the prognostic value of CD133 and MGMT and their possib... | DisGeNET | Detail |
| Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. | DisGeNET | Detail |
| Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase... | DisGeNET | Detail |
| MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primar... | DisGeNET | Detail |
| We applied artificial neural networks (ANNs) to understand the connections among polymorphisms of ge... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in high incidence region... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Moreover, TRIM24 regulates the expression of DNA repair enzyme O(6)-methylguanine-DNA methyltransfer... | DisGeNET | Detail |
| O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation has proven prognostic and pred... | DisGeNET | Detail |
| Justifications for withholding alkylating agent chemotherapy in patients with MGMT-unmethylated glio... | DisGeNET | Detail |
| A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. | DisGeNET | Detail |
| Methylated O6-methylguanin-DNA-methytransferase (MGMT) promoter methylation is associated with survi... | DisGeNET | Detail |
| Subtype specific drugs not only showed significant inhibition effects on the in vitro clonogenicity ... | DisGeNET | Detail |
| The most emblematic biomarker in glioblastoma is O6-methylguanine DNA-methyltransferase promoter met... | DisGeNET | Detail |
| O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is reported to be a prognostic an... | DisGeNET | Detail |
| These data indicated that MGMT methylation has prognostic significance in patients with newly diagno... | DisGeNET | Detail |
| The prognosis of MGMT promoter methylation in glioblastoma patients of different race: a meta-analys... | DisGeNET | Detail |
| DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with... | DisGeNET | Detail |
| Pine (Pinus morrisonicola Hayata) needle extracts sensitize GBM8901 human glioblastoma cells to temo... | DisGeNET | Detail |
| Treatment considerations for MGMT-unmethylated glioblastoma. | DisGeNET | Detail |
| MGMT promoter methylation and IDH1/2 mutation status in GBM were also evaluated. | DisGeNET | Detail |
| By univariate and multivariate Cox proportional hazard regression analysis, MGMT methylation status ... | DisGeNET | Detail |
| The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma m... | DisGeNET | Detail |
| One Gb subtype presented with low expression of the four genes mentioned, and of MGMT in a large por... | DisGeNET | Detail |
| Assessing MGMT methylation status and its current impact on treatment in glioblastoma. | DisGeNET | Detail |
| Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mut... | DisGeNET | Detail |
| Among these markers, a predictive value was reported in glioblastomas (GBM) for MGMT promoter methyl... | DisGeNET | Detail |
| Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy. | DisGeNET | Detail |
| Long-term survival following metronomic temozolomide was independent from MGMT and EGFRvIII status a... | DisGeNET | Detail |
| Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. | DisGeNET | Detail |
| Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed gl... | DisGeNET | Detail |
| Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. | DisGeNET | Detail |
| MGMT (O(6)-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic sil... | DisGeNET | Detail |
| Using the World Health Organization grade, histological subtype, and molecular variants (1p/19q code... | DisGeNET | Detail |
| MGMT testing--the challenges for biomarker-based glioma treatment. | DisGeNET | Detail |
| Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associa... | DisGeNET | Detail |
| (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas. | DisGeNET | Detail |
| Methylation status of the methyl-guanine methyltransferase (MGMT) promoter is associated with a favo... | DisGeNET | Detail |
| Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island ... | DisGeNET | Detail |
| IMP3 expression was significantly associated with the absence of mutations of IDH1 gene (P = 0.0001)... | DisGeNET | Detail |
| The O6-methylguanine-DNAmethyltransferase (MGMT) promoter methylation and 1p19q codeletion status ca... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MGMT-B gene promoter hypermethylation in patients with inflammatory bowel disease - a novel finding. | DisGeNET | Detail |
| Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer ris... | DisGeNET | Detail |
| We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo... | DisGeNET | Detail |
| Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer ris... | DisGeNET | Detail |
| O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal c... | DisGeNET | Detail |
| MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis. | DisGeNET | Detail |
| We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo... | DisGeNET | Detail |
| We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo... | DisGeNET | Detail |
| We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo... | DisGeNET | Detail |
| O6-methylguanine-DNA methyltransferase Leu84Phe and Ile143Val polymorphisms and risk of colorectal c... | DisGeNET | Detail |
| We found that the XRCC1-Arg399Gln AA and the MGMT-Leu84Phe CT+TT genotypes were associated with an i... | DisGeNET | Detail |
| Lack of influence of MGMT codon Leu84Phe and codon Ileu143Val polymorphisms on esophageal cancer ris... | DisGeNET | Detail |
| We found that the XRCC1-Arg399Gln AA and the MGMT-Leu84Phe CT+TT genotypes were associated with an i... | DisGeNET | Detail |
| We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colo... | DisGeNET | Detail |
| MGMT Leu84Phe gene polymorphism and lung cancer risk: a meta-analysis. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The present results indicated that the methylation of p16, CDH1, MGMT, and hMLH1 was both frequent a... | DisGeNET | Detail |
| MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MGMT promoter methylation is associated with temozolomide response and prolonged progression-free su... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| PRL-and GH-secreting PAs exist high expression of D2R, responding to dopamine agonists; Most PAs exi... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MGMT promoter methylation is associated with temozolomide response and prolonged progression-free su... | DisGeNET | Detail |
| Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in high incidence region... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| O6-methylguanine DNA methyltransferase (MGMT) methylation and protein expression have been related t... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and as... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primar... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Epigenetic inactivation of MGMT in HPCs necessitates the assessment of prognostic and predictive val... | DisGeNET | Detail |
| Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic panc... | DisGeNET | Detail |
| A single-nucleotide polymorphism (SNP) in an enhancer in the MGMT promoter was previously identified... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| These results suggest that tumor cells with methylated MGMT may undergo positive selection during TM... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Notably, we hypothesized that the inhibition of MGMT, a DNA damage response enzyme, by the over-expr... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in No... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Impact of O6-methylguanine-DNA methyltransferase expression on the drug resistance of clear cell ren... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to ... | DisGeNET | Detail |
| Notably, we hypothesized that the inhibition of MGMT, a DNA damage response enzyme, by the over-expr... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Meningeal hemangiopericytomas: a clinicopathological study with emphasis on MGMT (O(6) -methylguanin... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Thus MGMT hypermethylation can be used as a biomarker for esophageal cancer in high incidence region... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant gli... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| This study evaluates MGMT promoter methylation in meningeal HPCs to determine its role in HPC oncoge... | DisGeNET | Detail |
| In conclusion, MGMT methylation is central to the development of cancer that involves a stepwise car... | DisGeNET | Detail |
| Our data suggests that MGMT promoter hypermethylation could have a potential function as molecular b... | DisGeNET | Detail |
| O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that protects cells from carc... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The methylation frequencies of the MGMT gene promoter were found to be 29.5, 28.6 and 20 per cent fo... | DisGeNET | Detail |
| Also, based on their predictive value of response to therapy, the immunohistochemical evaluation and... | DisGeNET | Detail |
| A single-nucleotide polymorphism (SNP) in an enhancer in the MGMT promoter was previously identified... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| The present results indicated that the methylation of p16, CDH1, MGMT, and hMLH1 was both frequent a... | DisGeNET | Detail |
| MGMT gene silencing by promoter hypermethylation in gastric cancer in a high incidence area. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopath... | DisGeNET | Detail |
| Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer. | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| MGMT hypermethylation is also significantly higher in colorectal adenoma than in normal colorectal m... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarc... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Methylation-specific PCR was carried out to investigate the promoter methylation status of MGMT in b... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promot... | DisGeNET | Detail |
| The objective of this study was to determine the prognostic value of CD133 and MGMT and their possib... | DisGeNET | Detail |
| Prognostic value of MGMT methylation in colorectal cancer: a meta-analysis and literature review. | DisGeNET | Detail |
| Clinicopathological significance and potential drug target of O6-methylguanine-DNA methyltransferase... | DisGeNET | Detail |
| MGMT promoter methylation status in brain metastases from colorectal cancer and corresponding primar... | DisGeNET | Detail |
| We applied artificial neural networks (ANNs) to understand the connections among polymorphisms of ge... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Moreover, systemic delivery of scL-p53 down-modulates MGMT and induces apoptosis in intracranial GBM... | DisGeNET | Detail |
| The contrasting epigenetic role of RUNX3 when compared with that of MGMT and TIMP3 in glioblastoma m... | DisGeNET | Detail |
| We performed a systematic review to identify articles from the temozolomide era (2005-present) that ... | DisGeNET | Detail |
| Currently, O6-methylguanine-DNA methyltransferase(MGMT) promoter methylation is the most convincing ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Using a 10% cutoff, MGMT methylation was identified in 37% cases of glioblastoma and 0% of the non-n... | DisGeNET | Detail |
| Using a 10% cutoff, MGMT methylation was identified in 37% cases of glioblastoma and 0% of the non-n... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R399Q and OGG1-S326C), ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis. | DisGeNET | Detail |
| Polymorphic variants of base excision repair (APE1-D148E, XRCC1-R194W, XRCC1-R399Q and OGG1-S326C), ... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| O(6) -methylguanine DNA methyltransferase repairs platinum-DNA adducts following cisplatin treatment... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation st... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| In conclusion, MGMT methylation is central to the development of cancer that involves a stepwise car... | DisGeNET | Detail |
| DNA methylation of MGMT may regulate the expression of the gene and be involved in the development o... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Using western blotting it was shown that GA inhibited the protein expressions of MDC1, O(6)-methylgu... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Also, based on their predictive value of response to therapy, the immunohistochemical evaluation and... | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| NA | DisGeNET | Detail |
| Interestingly, the risk for glioma was dramatically increased in ionizing radiation exposure individ... | DisGeNET | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- dbSNP
- rs386493716 dbSNP
- Genome
- hg38
- Position
- chr10:129,467,190-129,770,983
- Variant Type
- snv
Genome browser